The RELATIVITY-123 study, which explored the efficacy of combination therapy of nivolumab and the novel anti-Lymphocyte Activation Gene 3 (LAG-3) antibody relatlimab as late-line chemotherapy for MSS colon cancer, also announced that the trial would be discontinued due to the expectation that the primary endpoint of OS would not be achieved [63]. Here, LAG3 is linked to colonic neoplasm.